GlassScriptPhysician profile
Timothy J Carrabine
NPI 1215015870
$109,297.81
in general payments reported to CMS, 2019-2025
30 companies · $1,591 in 2025
The $1,591 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $24K · 2021: $10K · 2022: $2,389 · 2023: $1,966 · 2024: $1,902 · 2025: $1,591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,159 · Consulting Fee: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,159.30 |
| Consulting Fee | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $41,891.73 | 2019-2025 | Tysabri, Vumerity, Plegridy |
| Genzyme Corporation | $37,082.93 | 2019-2025 | |
| Celgene Corporation | $16,898.52 | 2019-2025 | Zeposia |
| Genentech USA, INC. | $7,821.24 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $1,434.15 | 2019-2025 | |
| Emd Serono, INC. | $1,107.29 | 2019-2025 | Mavenclad |
| Tg Therapeutics, INC. | $735.81 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $698.70 | 2019-2025 | Ultomiris, Soliris |
| E.R. Squibb & Sons, L.L.C. | $200.03 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $177.57 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $140.99 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $119.62 | 2021-2024 | Acthar |
| Horizon Therapeutics Plc | $114.07 | 2022-2023 | Uplizna |
| Sanofi-Aventis U.S. LLC | $108.61 | 2019-2021 | |
| Banner Life Sciences, LLC | $108.55 | 2021-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $85.98 | 2025 | Tascenso Odt, Bafiertam |
| Vanda Pharmaceuticals INC. | $71.31 | 2025 | Ponvory |
| Genentech, INC. | $68.57 | 2019-2024 | Ocrevus |
| Jazz Pharmaceuticals INC. | $61.89 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $61.78 | 2019 | |
| Ani Pharmaceuticals, INC. | $58.82 | 2022-2024 | Purified Cortrophin Gel |
| Acorda Therapeutics, INC | $46.01 | 2022-2023 | Inbrija, Ampyra |
| Otsuka America Pharmaceutical, INC. | $44.78 | 2023-2024 | Nuedexta |
| Abbvie INC. | $41.29 | 2022-2024 | Vraylar |
| Amgen INC. | $28.91 | 2024-2025 | Uplizna |
| Validus Pharmaceuticals LLC | $21.89 | 2019 | |
| Mylan Specialty L.P. | $19.26 | 2023 | Glatiramer Acetate |
| Teva Pharmaceuticals USA, INC. | $18.80 | 2019 | |
| Sumitomo Pharma America, INC. | $15.62 | 2025 | Gemtesa |
| Ironwood Pharmaceuticals, INC | $13.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Carrabine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.